Bio-Safety and Bioethics
Biosafety as currently discussed in the International “Convention on Biological Diversity” (CBD) and designed to create internationally binding protocols on biosafety. The application of biotechnology to food and agriculture can bring not only potential risks and benefits as any technology can, but also concerns about the human dimensions coupled with biotechnology. These include both positive and negative impacts on stake holders, social institutions, economy and communities. Different areas associated with biosafety include: (i) Agriculture and food system issues (ii) Market and consumer issues (iii) Institutional issues, business issues and (iv) Social issues. Biosafety is the prevention of large-scale loss of biological integrity, focusing both on ecology and human health. These prevention mechanisms include conduction of regular reviews of the biosafety in laboratory settings, as well as strict guidelines to follow. The international Cartagena Protocol on Biosafety deals primarily with the agricultural definition but many advocacy groups seek to expand it to include post-genetic threats: new molecules, artificial life forms, and even robots which may compete directly in the natural food chain. ‘Biosafety’ means the need to protect human and animal health and environment from the possible adverse effects of the products of modern biotechnology. Bioethics is the study of the typically controversial ethical issues emerging from new situations and possibilities brought about by advances in biology and medicine. It is also moral discernment as it relates to medical policy and practice. Bioethicists are concerned with the ethical questions that arise in the relationships among life sciences, biotechnology, medicine, politics, law, and philosophy. The scope of bioethics can expand with biotechnology, including cloning, gene therapy, life extension, human genetic engineering, astroethics and life in space, and manipulation of basic biology through altered DNA, XNA and proteins. These developments will affect future evolution, and may require new principles that address life at its core, such as biotic ethics that values life itself at its basic biological processes and structures, and seeks their propagation.
Related Conference of Bio-Safety and Bioethics
41st International Conference on Next-Gen Biotechnology and Applications
Bio-Safety and Bioethics Conference Speakers
Recommended Sessions
- Animal Biotechnology
- Applied Biotechnology
- Bio-Safety and Bioethics
- Bioinformatics and Biomedicine Engineering
- Biomedical Engineering and Bio-Engineering
- Enzyme and Protein Engineering
- Food & Feed Biotechnology
- Genetic Engineering and Tissue Engineering
- Industrial and Microbial Biotechnology
- Marine, Aquatic and Ocean Biotechnology
- Medicine & Biotechnology
- Molecular Biotechnology
- Nano biotechnology
- Pharmaceutical Biotechnology
- Plant, Agriculture and Environment Biotechnology
Related Journals
Are you interested in
- Advancements in Analytical Techniques - ANALYTICA ACTA 2026 (France)
- Advancements in Biosimilar Development Technologies - Biosimilars 2026 (France)
- Advances in Genomic Biotechnology - Biotechnology 2025 (Spain)
- Agriculture Biotechnology - Euro Biotechnology 2026 (Italy)
- Analytical Challenges in Personalized Medicine - ANALYTICA ACTA 2026 (France)
- Analytical Chemistry in Agriculture - ANALYTICA ACTA 2026 (France)
- Analytical Chemistry in the Energy Sector - ANALYTICA ACTA 2026 (France)
- Analytical Techniques for Biotechnology - ANALYTICA ACTA 2026 (France)
- Analytical Techniques in Material Science - ANALYTICA ACTA 2026 (France)
- Animal Biotechnology - Euro Biotechnology 2026 (Italy)
- Artificial Intelligence and Digital Tools in Biotherapeutics - Biosimilars 2026 (France)
- Automation in Bioanalytical Laboratories - ANALYTICA ACTA 2026 (France)
- Bio-Safety and Bioethics - Euro Biotechnology 2026 (Italy)
- Bioanalytical Method Development and Validation - ANALYTICA ACTA 2026 (France)
- Biobetters: The Next Generation of Biologics - Biosimilars 2026 (France)
- Bioinformatics & Computational Biology - Euro Biotechnology 2026 (Italy)
- Bioinformatics and Computational Approaches - ANALYTICA ACTA 2026 (France)
- Biomaterials - Euro Biotechnology 2026 (Italy)
- Biomedical Biotechnology - Biotechnology 2025 (Spain)
- Biomedical Engineering & Applications - Euro Biotechnology 2026 (Italy)
- Biopharmaceuticals and Biologics - ANALYTICA ACTA 2026 (France)
- Biopharmaceuticals and Biosimilars - Biotechnology 2025 (Spain)
- Bioprocess and Fermentation Technology - Euro Biotechnology 2026 (Italy)
- Bioremediation and Biodegradation - Euro Biotechnology 2026 (Italy)
- Biosimilar Market Access and Reimbursement Policies - Biosimilars 2026 (France)
- Biosimilars in Oncology and Autoimmune Diseases - Biosimilars 2026 (France)
- Biosimilars in Rare and Orphan Diseases - Biosimilars 2026 (France)
- Biotechnology - Euro Biotechnology 2026 (Italy)
- Biotechnology and Global Health - Biotechnology 2025 (Spain)
- Biotechnology Applications - Euro Biotechnology 2026 (Italy)
- Biotechnology in Agriculture - Biotechnology 2025 (Spain)
- Biotechnology in Dentistry - Euro Biotechnology 2026 (Italy)
- Chemical Analysis and Sensing - ANALYTICA ACTA 2026 (France)
- Clinical and Forensic Analysis - ANALYTICA ACTA 2026 (France)
- Clinical Trials & Comparability Studies for Biosimilars - Biosimilars 2026 (France)
- Collaborative Models in Biosimilar Development - Biosimilars 2026 (France)
- Computational and Systems Biology - Biotechnology 2025 (Spain)
- Cost-Effectiveness and Health Economics of Biosimilars - Biosimilars 2026 (France)
- Data Integrity and Compliance in Analytical Chemistry - ANALYTICA ACTA 2026 (France)
- Emerging Contaminants and Analytical Challenges - ANALYTICA ACTA 2026 (France)
- Emerging Trends in Analytical and Bioanalytical Techniques - ANALYTICA ACTA 2026 (France)
- Environmental Analysis - ANALYTICA ACTA 2026 (France)
- Environmental Biotechnology - Biotechnology 2025 (Spain)
- Environmental Biotechnology - Euro Biotechnology 2026 (Italy)
- Enzyme and Protein Engineering - Euro Biotechnology 2026 (Italy)
- Evolving Trends and Innovations in Biosimilar Development and Access - Biosimilars 2026 (France)
- Food and Beverage Analysis - ANALYTICA ACTA 2026 (France)
- Food and Feed Biotechnology - Euro Biotechnology 2026 (Italy)
- Formulation and Delivery Systems for Biologics - Biosimilars 2026 (France)
- Future Biotherapeutics: Cell and Gene Therapies - Biosimilars 2026 (France)
- Future of Monoclonal Antibodies and Fusion Proteins - Biosimilars 2026 (France)
- Future Trends in Biotechnology - Biotechnology 2025 (Spain)
- Genetics and Molecular biotechnology - Euro Biotechnology 2026 (Italy)
- Genomics and Molecular Biology Analysis - ANALYTICA ACTA 2026 (France)
- Global Trends and Challenges in Biosimilar Adoption - Biosimilars 2026 (France)
- High-Resolution Techniques - ANALYTICA ACTA 2026 (France)
- Imaging Techniques and Microscopy - ANALYTICA ACTA 2026 (France)
- Immunogenicity Assessment and Risk Management - Biosimilars 2026 (France)
- Industrial and Manufacturing Biotechnology - Euro Biotechnology 2026 (Italy)
- Industrial Biotechnology - Biotechnology 2025 (Spain)
- Industrial Scale-Up and Bioprocessing - Biotechnology 2025 (Spain)
- Instrumentation and Automation in Analytical Chemistry - ANALYTICA ACTA 2026 (France)
- Interchangeability and Substitution Policies - Biosimilars 2026 (France)
- Manufacturing and Quality Control of Biosimilars - Biosimilars 2026 (France)
- Marine Biotechnology - Biotechnology 2025 (Spain)
- Marine Biotechnology - Euro Biotechnology 2026 (Italy)
- Medical Biotechnology - Euro Biotechnology 2026 (Italy)
- Metabolomics and Proteomics - ANALYTICA ACTA 2026 (France)
- Microbial Biotechnology - Euro Biotechnology 2026 (Italy)
- Microbial Biotechnology - Biotechnology 2025 (Spain)
- Nano Biotechnology - Euro Biotechnology 2026 (Italy)
- Nanomaterials and Nanotechnology in Analysis - ANALYTICA ACTA 2026 (France)
- Oncolytic Biotechnology - Euro Biotechnology 2026 (Italy)
- Patient and Physician Perspectives on Biosimilar Use - Biosimilars 2026 (France)
- Pharmaceutical Analysis - ANALYTICA ACTA 2026 (France)
- Pharmaceutical Biotechnology and Drug Design - Euro Biotechnology 2026 (Italy)
- Pharmacovigilance and Post-Marketing Surveillance - Biosimilars 2026 (France)
- Plant and Forest Biotechnology - Euro Biotechnology 2026 (Italy)
- Quality by Design (QbD) in Analytical Method Development - ANALYTICA ACTA 2026 (France)
- Regenerative Medicine and Analytical Techniques - ANALYTICA ACTA 2026 (France)
- Regulatory Pathways and Global Harmonization - Biosimilars 2026 (France)
- Spectroscopic Techniques - ANALYTICA ACTA 2026 (France)
- Stem Cell and Regenerative Medicine - Biotechnology 2025 (Spain)
- Stem Cell Biotechnology and Regenerative Medicine - Euro Biotechnology 2026 (Italy)
- Surface and Interface Analysis - ANALYTICA ACTA 2026 (France)
- Synthetic Biology and Bioengineering - Biotechnology 2025 (Spain)
- Vaccine Development and Immunotherapy - Biotechnology 2025 (Spain)
- Workshops and Hands-On Training - ANALYTICA ACTA 2026 (France)

